Skip to main content
. 2006 Feb 11;332(7537):325–329. doi: 10.1136/bmj.38733.466748.7C

Table 4.

Mortality up to day 32 in older (≥60 years) medical patients randomised to the anticoagulant fondaparinux or placebo

Variable Fondaparinux group (n=425) Placebo group (n=414)
Death from any cause:
Fatal pulmonary embolism 3 7
Fatal bleeding* 2 1
Other causes 9 17
Total No (%) 14 (3) 25 (6)
*

None occurred during study treatment.